Navigation Links
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Date:8/15/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 15, 2013 /PRNewswire/ -- Data published in The Lancet showed that elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (TRADJENTA®), marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY), experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the overall safety and tolerability profile of linagliptin was similar to placebo.1

Linagliptin, which is marketed as TRADJENTA® (linagliptin) tablets in the U.S., is a once-daily 5-mg tablet used along with diet and exercise to improve glycemic control in adults with T2D. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). TRADJENTA has not been studied in patients with a history of pancreatitis and it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRADJENTA.

"Elderly individuals represent approximately 15 percent of people with type 2 diabetes worldwide,2" said Professor Anthony H. Barnett, MD, FRCP, Heart of England NHS Foundation Trust and University of Birmingham, United Kingdom. "This study may help inform treatment decisions for improving glycemic control in the elderly."

The publication reports on a 24-week, double-blind, parallel-group, multinational, phase III study in 241 elderly people (=70 years; mean age, 74.9 years) with T2D randomized to receive linagliptin 5 mg (n=162) or placebo (n=79), in addition to existing glucose-lowering
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
3. Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
4. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
5. Award-Winning Spot Vision Screener To Be Demonstrated At USA/Canada Lions Leadership Forum
6. Feasibility of Artificial Pancreas System Demonstrated in Real-World Setting
7. Haemonetics Reports 1st Quarter Fiscal 2014 Revenue Up 24%; Adjusted EPS of $0.46 Up 46%; Adjusted Operating Margin Improvement of 270 Basis Points; and Significant Progress on Planned Manufacturing Transformation
8. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
9. Groundbreaking UK Study Confirms Significant Reduction in Hospital Superbug Pathogens with TRU-D SmartUVC Disinfection Robot
10. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
11. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Dec. 7, 2010 Graymark Healthcare, Inc. (Nasdaq: ... of substantially all the assets of its ApothecaryRx,s retail ... ApothecaryRx operated 18 pharmacies across five states. ... business of providing comprehensive care for sleep disorders, primarily ...
... NEW YORK, Dec. 7, 2010 The NuVal™ ... (ActiveHealth®), a provider of evidence-based health information technology ... to bring new tools online to help ActiveHealth ... http://photos.prnewswire.com/prnh/20100119/NE39897LOGO) Beginning in December, NuVal,s nutrition ...
Cached Medicine Technology:Graymark Healthcare to Focus on Treatment of Sleep Disorders with Completed Sale of Independent Pharmacy Business Assets to Walgreens 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 2ActiveHealth Management to Deliver Innovative NuVal™ Nutritional Scoring System Through Health Website 3
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , , , ... , LOUISVILLE, Ky., July 23 University of Louisville physicians ... Hospital in Louisville, KY, on July 17, 2009. The procedure is part ... treat heart disease. , , ...
... SAN DIEGO, July 23 Orexigen Therapeutics, Inc. ... priced an underwritten public offering of 10,000,000 shares of its ... proceeds, after estimated underwriting discounts and commissions and estimated expenses, ... a 30-day option to purchase up to an additional 1,500,000 ...
... Ohio, July 23 Estimates place the prevalence of physical ... of the global adult population according to THE ORTHOPAEDIC ... , , "Our sources indicate ... increased 25 percent over the past ten years, and those ...
... DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology ... is pleased to announce that it has been granted ... per "MIT China" requirements, from the "China Medical City" ... half years. , The operation facility will harbor all ...
... , , , ... TELEHOUSE America ( www.telehouse.com ) ... exchanges, and managed IT services, today announced it is offering ... prevention (DLP) consulting services as part of its Manage-E ...
... , , , ... Media, LLC., a new media and publishing company, today announced the ... a weekly web digest devoted to covering the ideas, technologies, business ... on opportunities for progress in healthcare, Healthspottr delivers select, forward-thinking content ...
Cached Medicine News:Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 2Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 3
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: